Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced that the first subject has been dosed in a Phase 1 ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

USA: Researchers have found in a new study that even in the absence of anemia, iron deficiency (ID) during adolescence is ...

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

How new diagnostic pathways can support earlier diagnosis and appropriate management in patients with lower gastrointestinal ...

A new study published in the Journal of American Medical Association found that in patients with myocardial infarction (MI) ...

How one of the oldest components of the human immune system can trigger a mysterious and little-understood syndrome.

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

Clinical trial data suggest balneotherapy may improve symptoms of fatigue, pain, and anxiety in patients with long COVID and ...

Even on stable days, people with SCD live with a range of complications: chronic anaemia, joint pain, slowed growth, ...